Redivia is a spin-off project at TU Dresden. We will accelerate and improve success rates in drug discovery using innovative software to tackle key hurdles faced by biopharma customers. Disruptive virtual screening technologies combined with real-world drug development expertise allow Redivia to provide unique insight into the process and identify the optimal solution for discovery scientists.
Redivia addresses needs in drug design, finding new applications for old drugs or failed candidates, identification of “off-targets” responsible for unwanted side-effects and extending the lifetime of approved drugs by identifying new therapeutic areas.
Disruptive Software Technologies
Redivia’s success builds on disruptive software technologies bundled in the Redivia Discovery Engine, which efficiently identifies drug candidates based on the geometry of protein binding sites and their interactions with compounds. The two most important algorithms in the RDDiscovery Engine are RDAlign and RDInteract, offering novel means to explore the drug-target space at a ground-breaking level of precision.
The major challenge to bridge chemical and target space far beyond chemical similarity and homology is overcome with cutting-edge algorithms based on local alignments of target structures (binding site similarity) and analysis of non-covalent interactions (drug-target interaction profiles).
Over 30 Years of Experience
Our team combines best in class research and over 30 years of experience in biotech spin-out management.
Joachim Haupt, PhD
Head of Technology Development
Gary Jennings, PhD
Jörg Heinrich, PhD
Sebastian Salentin, PhD
Prof. Michael Schroeder
Partnerships, Questions, Inquiries
Redivia Biotechnology Center of TU Dresden
Tatzberg 47 01307 Dresden Germany
Gary Jennings, PhD Business Development
+49 351 463 40063
The project Redivia is funded under the EXIST program by the German Federal Ministry for Economic Affairs and Energy and the European Social Fund.